Kornimate/medical-research-clean huggingface dataset:
comparison of the balance board and perceptual motor therapy in children with cerebral palsy.

Conditions: Cerebral Palsy

Summary: various studies have worked on the sitting balance of cerebral palsy (cp) with gross motor function classification system (gmfcs) level i-iii with a sample greater than 30, there is no data available to compare the effect of a balance board and perceptual motor therapy to improve sitting in gmfcs level iv and v with a sample greater than 30. this study will add the authenticity to literature with a large sample size and affect the severity of the condition.

this study will compare the effect of balance board therapy and perceptual motor therapy to improve sitting in children with cerebral palsy. previous studies have worked on the sitting balance of cerebral palsy (cp) with gross motor function classification system (gmfcs) level i-iii with a sample greater than 30, there is no data available to compare the effect of a balance board and perceptual motor therapy to improve sitting in gmfc level iv and v with a sample greater than 30. this study will add the authenticity to literature with large sample size and affect the severity of the condition. in addition, the patients with diagnosed cerebral palsy with gmfcs levels iv and v will be benefited from this study; an exercise program will help them to improve their sitting ability. a total of 88 cerebral palsy patients will be included by dividing them into two groups (a, b). 1 hour of exercise session will be performed three times per week for 12 weeks with a total of 36 sessions. both groups will receive 30 minutes of conventional physical therapy. in addition, group a will receive balance board therapy in the remaining 30 minutes while group b will receive perceptual motor therapy in the remaining 30 minutes. data will be collected at baseline, at 4 weeks, at 8 weeks and at 12 weeks after intervention from both groups. the sitting balance will be measured by using gross motor function measure scale (gmfm 88) and trunk control motor scale (tcms).

Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with cp gmfc level iv and v * both male/female * participants with the age ranges from 1.5 years to 5 years exclusion criteria: * patients diagnosed with gmfc level i, ii and iii * participants taking botulinum toxin * participants diagnosed with auditory and visual impairments * participants diagnosed with mental impairments/ unable to understand the commands * participants diagnosed with any other comorbid conditions like (obesity, cardiovascular impairments) * participants who are not willing to participate

Keywords: cerebral palsy gmfc iv gmfc v balance board perceptual motor therapy
discordant hormonal status of breast cancer.

Conditions: Malignant Neoplasm of Breast.

Summary: the purpose of this study is to determine discordant hormonal status of primary breast tumor and metastatic breast cancer cells at regional lymph nodes in node positive breast cancer patients.

hormonal status between primary breast tumor and axillary lymph node were analyzed.

Eligibility criteria:
inclusion criteria: * breast cancer patients stage i,ii and iii with axillary lymph nodes metastasis. exclusion criteria: * breast cancer patients stage i,ii and iii without axillary lymph nodes metastasis.
the effectiveness of laparoscopic treatment of superficial endometriosis for managing chronic pelvic pain

Conditions: Endometriosis; Pelvic Pain

Summary: endometriosis is a chronic, incurable condition that affects about 10% of women of reproductive age. it is defined as a growth of cells similar to the womb lining outside of the womb in the pelvis, and is associated with chronic pelvic pain, excessive period pain, pain with sexual intercourse and difficulties in getting pregnant. if the disease is found only on the lining of the pelvis it is known as "superficial peritoneal" and is usually treated during a laparoscopic surgery by cutting out (excision) or burning off (ablation). however, many women do not find improvement in their symptoms after the surgery and can have complications from the procedure. the aim of this study is to determine if removal of the superficial peritoneal endometriosis improves pain symptoms and quality of life, which method of removal (excision or ablation) is more effective or if surgical removal is of no benefit to the patients and can potentially cause harm. the investigators plan to recruit up to 90 women from four nhs hospitals in scotland over a period of 12 months. women who are attending gynaecology departments with pelvic pain who have not previously had a diagnosis of endometriosis via laparoscopy will be approached. patients will be asked to read an information sheet about the trial. women who consent to the trial will be randomised during the surgery, if superficial endometriosis is found, to either having the endometriosis removed or not. for this pilot, follow up will be at 3 and 6 months (and obtain permission to continue to follow them up at 12 and 24 months should time and finding permit). patients who do not consent to take part in the trial will be asked if the investigators can collect data on their demographics and reasons on why they did not wish to take part.


Eligibility criteria:
inclusion criteria: * undergoing laparoscopy for the investigation of chronic pelvic pain * in order to be randomised, isolated superficial peritoneal endometriosis (spe) must be identified at laparoscopy (macroscopically) * able to give informed consent exclusion criteria: * previous surgical diagnosis of endometriosis * pregnant or are actively trying for pregnancy within the next six months * deep endometriosis or ovarian endometrioma on imaging or at laparoscopy * peritoneal 'pockets' only noted at laparoscopy

Keywords: endometriosis laparoscopy pelvic pain
auditory neuropathy and cochlear implants

Conditions: Cochlear Implants; Auditory Neuropathy

Summary: the electrical stimulation generated by the cochlear implant (ci) may improve the neural synchrony and hence contribute to the development of auditory skills in patients with auditory neuropathy / auditory dys-synchrony (an/ad). goal: the goal of the research was to evaluate the auditory performance and the characteristics of the electrically evoked compound action potential (ecap) in a group of 18 cochlear implants recipients with an/ad.the auditory perception was evaluated by sound field thresholds and speech perception tests. to evaluate ecap's characteristics, the threshold and amplitude of neural response together with the amplitude growth and recovery functions were evaluated at 80hz stimulation rate.the ci was seen as an efficient resource to develop auditory skills in 94% of the an/ad patients considered by the research. the auditory perception benefits as well as the possibility to measure the ecap showed that the electrical stimulation could compensate the neural dys-synchrony caused by the an/ad. however, a unique clinical procedure cannot be proposed at this point. therefore, a careful and complete evaluation of each an/ad patient before recommending the cochlear implant is advised


Eligibility criteria:
inclusion criteria: * all children with an/ad who had received the cochlear implant during the research´s period.
regional lung inflammation and expansion in mechanically ventilated patients - a pet/ct study

Conditions: Respiratory Failure

Summary: the goal of this study is to investigate acute respiratory distress syndrome (ards) and septic lung with positron emission tomography (pet) imaging and to examine the distribution of inflammation, as measured by neutrophil metabolic activity.


Eligibility criteria:
inclusion criteria: group 1 * mechanically ventilated patients scheduled to undergo a ct scanning for their routine clinical care * more than 24 hours of mechanical ventilation * less than 15 days of mechanical ventilation if patient presents ali/ards (in order to exclude the late, fibrotic, stage of ards) group 2 * mechanically ventilated patients with a diagnosis of sepsis * less than 96 hours of mechanical ventilation exclusion criteria: * age less than 18 years * hemodynamic instability, defined as: systolic blood pressure (sbp) \< 90 mmhg that is not adequately stabilized by vasopressors or inotropic agents. for these purposes, sbp will not be considered "adequately stabilized" if the dose of the vasopressor/inotrope has not been stable for at least one hour * hypoxemia, defined as: pao2 \< 70 mmhg on an inspired oxygen fraction (fio2) greater than or equal to 0.9; fio2 greater than or equal to 0.8 at baseline * hemodynamic and/or respiratory instability (as defined, respectively, in 2 and 3), that develop when the patient is mobilized during routine nursing care such as repositioning/washing the patient or changing their bed linens * hemodynamic and/or respiratory instability (as defined, respectively, in 2 and 3), that develop when a 15-25 second respiratory pause is introduced as per the study protocol. this will be tested by inducing such a pause prior to transporting the patient * patients must be deemed by the treating clinical staff to be able to tolerate leaving the icu for 90 minutes (40-60 minute imaging time + 30 minute safety margin). treating md, rt, and rn must all agree that the patient is stable for transport * any acute or chronic condition which, in the opinion of the investigator, might confound the imaging measurements (such as, but not limited to, severe bronchospasm, pulmonary infection, and lung tumor) * "air leaks" requiring tube thoracostomy (e.g., pneumothorax, bronchopleural fistula) * pregnancy (since this is a study which would expose a fetus to radiation risk) * patients who have neither an arterial nor a central venous line at the time of the enrollement

Keywords: computed tomography and positron emission tomography respiration, artificial respiratory distress syndrome, adult
intramedullary femoral reaming, human study

Conditions: Pulmonary Complications; Organ Failure; Systemic Inflammatory Response Syndrome

Summary: to what extent the cardiopulmonary and inflammatory response is affected by initial femoral intramedullary nailing in the already traumatized and inflammatory activated patient was analyzed in the present study with the attention to survey the additional burden of this operative treatment. the patients are monitored with a pulmonary catheter, and blood samples for coagulation, fibrinolysis, complement and cytokine response are withdrawn pre-, per- and postoperatively. the study is partly randomized 1)where delayed intramedullary nailing is compared with primary nailing of the femur, and 2) a new reaming technique (ria) is compared with a standard reaming technique (tr).

to what extent the cardiopulmonary and inflammatory response is affected by initial femoral intramedullary nailing in the already traumatized and inflammatory activated patient was analyzed in the present study with the attention to survey the additional burden of this operative treatment. the patients are monitored with a pulmonary catheter, and blood samples for coagulation, fibrinolysis, complement and cytokine response are withdrawn pre-, per- and postoperatively. the study is partly randomized 1)where delayed intramedullary nailing is compared with primary nailing of the femur, and 2) a new reaming technique (ria) is compared with a standard reaming technique (tr).

Eligibility criteria:
inclusion criteria: * femoral shaft fracture suitable for intramedullary nailing * \< 24 hours postinjury exclusion criteria: * previous fracture of the femur * pathological fracture * femur deformities * pregnancy * previous intramedullary nailing or external fixation

Keywords: intramedullary reaming inflammatory response human femoral shaft fracture reamer-irrigator-aspirator
assess the effect of dehydroepiandrosterone (dhea) or other androgenic agents over markers of ovarian reserve

Conditions: Healthy Women; Infertility, Female

Summary: this study was conducted to evaluate the effect of a continuous administration of dehydroepiandrosterone (dhea) or other androgenic agents on ovarian reserve markers in women with diminished ovarian reserve (rod), such as antral follicle count (afc) and anti-müllerian hormone (amh) concentrations.

healthy women attending the clinic of the mother and health research institute (idimi) were invited to participate, if they could not become pregnant due to surgical sterilization, and if they presented no contraindications to use androgen therapy. project objectives : the general objective was to evaluate pharmacokinetic parameters of three vaginal rings containing dhea, testosterone, or combination of both hormones in women. secondary objectives were to assess effects on the hormonal profile, tolerability and incidence of adverse events. * dhea and/or, testosterone levels * estradiol, follicle stimulating hormone (fsh), sex hormone binding globulin (shbg), androstenedione, morning cortisol, insulin growth factor 1 (igf-1) levels * tolerability and safety assessment by the use of the vaginal ring. * the incidence of adverse events

Eligibility criteria:
inclusion criteria: 1. women between 38 and 45 years of age who have not used hormonal contraceptive methods at least for the past two months, or who have been surgically sterilized, with no contraindications for androgenic therapy. 2. women with preserved menstrual cycles. 3. women smoking less than 5 cigarettes daily. 4. anti-müllerian hormone (amh) between 0.5-1.1 ng/ml 5. total antral follicle count (afc) 5-7 exclusion criteria: 1. women receiving medications that interact with dhea metabolism (anastrozole, exemestane, fulvestrant, insulin, letrozole, tamoxifen, triazolam). 2. women with diabetes mellitus 3. women with untreated or decompensated endocrine disorders 4. women with a prior history of ovarian surgery or oophorectomy

Keywords: hormone replacement therapy
evaluation of an intra auricular device as a treatment for painful temporo-mandibular disorders

Conditions: Temporomandibular Disorder; Pain; Psychosocial Impairment; Myofascial Pain

Summary: background: an innovative, non-invasive, and reversible intra auricular device (iad) has recently been introduced to treat temporomandibular muscle and joint disorders.aim: to evaluate the effects of the iad on pain, psychosocial domain and pressure pain threshold (ppt) of masticatory muscles in patients with tmd pain. methods: ten subjects with tmd pain and with pain intensity higher than 30 mm on a vas scale were included in the study. patients received the iad and counselling. assessments included questionnaires of the dc/tmd axis ii questionnaires (characteristic pain index, interference, jaw functional limitation scale, patient health questionnaire 9, patient health questionnaire 15, generalized anxiety disorder scale, oral behavior checklist and oral health impact profile-22, axis i clinical examination and ppts at baseline (t0), after one month (t1), three months (t2) and six months (t3) from the first use of the device. ppts were measured at anterior temporalis muscles, masseter muscles and right thenar as a control site.the shapiro-wilk test was used for the normal distribution of data. the difference among the longitudinal timepoints for variable was analysed with anova. statistical significance was accepted at p \< 0.05.

the goal of ths study is to evaluate the effects of a new intra auricular device, the iad, on pain, psychosocial domain and pressure pain threshold (ppt) of facial muscles in patients with diagnosis of tmd pain according to the diagnostic criteria of temporomandibular disorders

Eligibility criteria:
inclusion criteria: * age \>18 * tmd-pain diagnosed according to the dc/tmd (myalgia, myofascial pain, arthralgia, headache attributable to tmd) * disc displacement with reduction exclusion criteria: * disc displacement without reduction * intermittent locking * degenerative tmj disorder * craniofacial anomaly * history of prior tmj * orthognathic surgery * recent (within the past six months) trauma to the face or jaw * current, active orthodontic treatment * severe mental health disorder

Keywords: pressure pain threshold intra auricular device
regional multicenter study to evaluate tolerability and efficacy of taf/ftc/rpv combination (odefsey ®) in prevention of sexual or blood exposure to hiv

Conditions: Hiv

Summary: prospective, multicenter study to evaluate tolerability, adherence and efficacy of a 28-day course of taf/ftc/rpv, an hiv post-exposure prophylaxis after a potential sexual or blood exposure to hiv. at baseline, participants are prescribed taf/ftc/rpv and a blood test. at w6, all participants are contacted by phone to evaluate completeness and tolerability of the taf/ftc/rpv regimen.

at baseline, participants seek care in one of the centers of " pays de la loire " area after a potential hiv exposure. they receive taf/ftc/rpv, one pill taken with food once daily for 28 days according to national guidelines. they have to start this post-exposure prophylaxis within 48 hours after the hiv exposure. at inclusion, participants give their written consent to have their data recorded in an electronic medical record nadis® and their oral consent after reading the study information letter. a blood test is prescribed to examine biological variables (hiv, hbv, hcv serologies, tpha vdrl, alt/ast, hemogram and serum creatinine). characteristics of participants and context of the risk are collected in the electronic medical record nadis®. a blood test is prescribed at w2, w6 and w12 to evaluate tolerability and efficacy of the treatment. at w6, all participants are contacted by phone call to evaluate completeness and tolerability of the taf/ftc/rpv regimen. they are reminded to have a blood test done at w6 and w12.

Eligibility criteria:
inclusion criteria: * subject seeking care in one of the french cegidd or in one of the french centers of " pays de la loire " area (chu nantes, chu angers, chd la roche sur yon, ch le mans, ch saint nazaire, ch laval) after a potential sexual or non-sexual hiv exposure * adult ≥18 years old * oral informed consent * written informed consent to have their data recorded in an electronic medical record ("nadis" software). * indication of hiv post-exposure prophylaxis according to the french guidelines exclusion criteria: * subject not willing or refusing to participate * subject on legal protection * hiv positive status * pregnancy or breastfeeding * already treated by pre exposure prophylaxis * already included in the study

Keywords: hiv exposition treatment sexual risk blood risk
circulating tumor dna exposure in peripheral blood

Conditions: Colorectal Cancer; Pancreatic Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Bladder Cancer; Melanoma; Ovarian Cancer; Adrenocortical Cancer; Breast Cancer; Other Cancer

Summary: this is a prospective, multi-center, blinded feasibility study. the objective of this study is to test the feasibility of the detection of tumor dna of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor dna (ctdna).

this prospective, multi-center, feasibility study represents a feasibility study to determine the potential of circulating tumor dna exposure in peripheral blood using a novel process in a sample of patients with different types of malignant organ tumors and a control cohort without malignant disease. the study applies a new process to detect ctdna and other molecular markers in peripheral blood using: a collection of de-identified blood specimen and clinical data from up to 10,000 participants from clinical sites across the united states and europe. data collected will include the following: demographics, tumor characteristics, information about treatment, specimen assessment, postoperative assessment clinical information, and follow-up at intermittent future time points, for up to 15 years. the study test(s) to be used in this protocol is a multiplexed primer and probe design developed, that allows detecting a wider set of mutations at a higher sensitivity then conventional sequencing-based method. this novel process is currently being investigated at quantgene inc.

Eligibility criteria:
inclusion criteria: * this study will include subjects that are diagnosed with a malignancy (cohort 1) and a negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2). * subjects of both cohorts must: * be of age ≥ 18 * provide written consent for study participation * subject of cohort 1 must: * have a diagnosis of a malignancy in clinical stage 0 to iv including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma subjects of cohort 2 must: • meet the listed matching criteria exclusion criteria: * subjects of cohort 1 must not: have been treated for above diagnosed malignancy * subjects of cohort 2 must not: * have been diagnosed/treated for a malignancy previously
long-term maintenance with ketamine and esketamine for reduction of suicide in high-risk patients with depression

Conditions: Major Depressive Disorder

Summary: the study will consist of a 24-week-long trial examining outcomes in patients with major depressive disorder and suicidal ideation who will receive intravenous (iv) ketamine and intranasal (in) esketamine, compared to a large sample of matched historical controls. patients will be recruited from an inpatient psychiatric unit. eligible patients who provided informed consent will be enrolled in the study that will include a eight iv ketamine treatments, 13 esketamine treatment visits, seven long assessment visits, five short assessment visits, and daily surveys. the study will examine the feasibility, tolerability, and efficacy of repeated iv ketamine followed by esketamine, as well as predictors of treatment response.


Eligibility criteria:
inclusion criteria: 1. inpatient at a psychiatric unit at mgh 2. male and female, 18-70 years of age 3. diagnosis of major depressive disorder, single or recurrent, based on dsm-5 criteria, and currently experiencing a major depressive episode (mde) at least eight weeks in duration, prior to screening 4. current suicidal ideation 5. in good general health, as ascertained by medical history, physical examination, clinical laboratory evaluations, and/or ecg 6. a status of non-childbearing potential or use of an acceptable form of birth control 7. access to a mobile phone or computer with internet connection 8. ability to read, understand, and provide written and dated informed consent prior to screening 9. has a treating psychiatrist, either prior to admission or at discharge from the inpatient unit exclusion criteria: 1. any history of previous treatment with iv ketamine 2. pregnant or breastfeeding 3. a status of childbearing potential and is not willing to use birth control during the study 4. unstable medical illness 5. current diagnosis of a moderate to severe substance use disorder, within the last six months prior to screening based on dsm-5 criteria 6. history of bipolar disorder, or any psychotic symptoms in the current or previous depressive episodes 7. an axis i or axis ii disorder, which at screening is clinically predominant to their mdd or has been predominant to their mdd at any time within six months prior to screening (i.e., eating disorder, ocd, ptsd) 8. currently receiving ect treatment 9. currently receiving frequent or high dose benzodiazepines, opiates, barbiturates, or other cns depressant medications 10. has dementia, delirium, amnestic, or any other primary cognitive disorder 11. has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results 12. inability to consent to or comply with the study procedures. 13. other medical issues that might affect safety, study participation, or confound interpretation of study results 14. inability to comply with study safety procedures, including having reliable escorts to and from visits

Keywords: depression suicidal ideation